C57BL/6-Il4tm2(IL4)Bcgen Il4ratm1(IL4RA)Bcgen Il13tm1(IL13)BcgenIl13ra1tm1(IL13RA1)BcgenTnfrsf4tm1(TNFRSF4)Bcgen Tnfsf4tm1(TNFSF4)Bcgen/Bcgen • 113595
| Product name | B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice |
|---|---|
| Catalog number | 113595 |
| Strain name | C57BL/6-Il4tm2(IL4)Bcgen Il4ratm1(IL4RA)Bcgen Il13tm1(IL13)BcgenIl13ra1tm1(IL13RA1)BcgenTnfrsf4tm1(TNFRSF4)Bcgen Tnfsf4tm1(TNFSF4)Bcgen/Bcgen |
| Strain background | C57BL/6 |
| NCBI gene ID | 3565,3566,3596,3597,7293,7292 (Human) |
| Aliases | BCGF-1, BCGF1, BSF-1, BSF1, IL-4; CD124, IL-4RAA, IL4R; IL-13, P600; CD213A1, CT19, IL-13Ra, NR4; ACT35, CD134, IMD16, OX40, TXGP1L; CD134L, CD252, GP34, OX-40L, OX4OL, TNLG2B, TXGP1 |
Gene targeting strategy for B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice.
The exons 1-4 of mouse Il4 gene that encode the full length coding sequence were replaced by human IL4 exons 1-4 in B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice. The exons 4-7 of mouse Il4ra gene that encode the extracellular region coding sequences were replaced by human IL4RA exons 4-7 in B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice. The exons 1-4 of mouse Il13 gene that encode the full length coding sequence were replaced by human IL13 exons 1-4 in B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice. The exons 2-9 of mouse Il13ra1 gene that encode the extracellular protein were replaced by human IL13RA1 exons 2-9 in B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice. The exons 1-5 of mouse OX40 gene that encode the extracellular domain were replaced by human OX40 exons 1-5 in B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice. The exons 2-3 of mouse Ox40l gene that encode the extracellular region were replaced by human OX40L exons 2-3 in B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice.
The B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice were obtained by breeding B-hIL4/hIL4RA/hIL13/hIL13RA1 mice with B-hOX40/hOX40L mice.
Efficacy of anti-human OX40L antibody amlitelimab analog and anti-human IL4RA antibody dupilumab analog in B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice. (A&B) Ear thickness and body weight changes during the treatment. (C&D) Total IgE levels in serum. The results showed that compared to the untreated group (G2), the group of mice treated with amlitelimab analog (provided by a client) or dupilumab analog (provided by a client) showed a significant reduction in ear thickness. Serum was collected at the study endpoint. IgE level was analyzed by ELISA. The results showed that the levels of total IgE in mice treated with amlitelimab analog or dupilumab analog was lower than that in untreated mice. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test. *P < 0.05, **P < 0.01, ***P < 0.001.
H&E staining of AD model in B-hIL4/hIL4RA/hIL13/hIL13RA1/hOX40/hOX40L mice. Ear tissues were collected at the study endpoint and analyzed with H&E staining. The results showed that compared to the untreated group (G2), the group of mice treated with amlitelimab analog or dupilumab analog showed a significant reduction in epidermal thickness and pathological score of ear skin. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. AD: Atopic dermatitis.
